What is the recommended dosage of ceftazidime‑avibactam for adults and pediatric patients, including adjustments for renal impairment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ceftazidime-Avibactam Dosage

For adults with normal renal function, administer ceftazidime-avibactam 2.5 grams (ceftazidime 2 grams and avibactam 0.5 grams) intravenously every 8 hours over 2 hours. 1

Adult Dosing

Standard Dosing (Normal Renal Function)

  • Dose: 2.5 grams IV every 8 hours (ceftazidime 2 g + avibactam 0.5 g)
  • Infusion time: 2 hours
  • Duration:
    • Complicated intra-abdominal infections (cIAI): 5-14 days
    • Complicated urinary tract infections (cUTI): 7-14 days
    • Hospital-acquired/ventilator-associated pneumonia (HABP/VABP): 7-14 days 1

Important: For cIAI, combine with metronidazole 0.5 g IV every 8 hours 1

Renal Impairment Adjustments

Dosing adjustments are critical because both ceftazidime and avibactam are predominantly renally cleared (80-90% and 97% unchanged in urine, respectively) 1. Monitor creatinine clearance at least daily in patients with changing renal function and adjust doses accordingly 1.

CrCl (mL/min) Dose Frequency
31-50 1.25 g (CAZ 1 g + AVI 0.25 g) Every 8 hours
16-30 0.94 g (CAZ 0.75 g + AVI 0.19 g) Every 12 hours
6-15* 0.94 g (CAZ 0.75 g + AVI 0.19 g) Every 24 hours
≤5* 0.94 g (CAZ 0.75 g + AVI 0.19 g) Every 48 hours

*Administer after hemodialysis on dialysis days 1

Critical caveat: Recent evidence suggests that renal dose reduction may be independently associated with higher mortality in KPC-producing Klebsiella pneumoniae bloodstream infections 2. This underscores the importance of optimizing exposure through extended infusions or therapeutic drug monitoring when feasible, particularly in severe infections.

Pediatric Dosing

Ages 2 to <18 Years (eGFR >50 mL/min/1.73 m²)

  • Dose: 62.5 mg/kg IV every 8 hours (maximum 2.5 grams)
    • Ceftazidime 50 mg/kg + avibactam 12.5 mg/kg
    • Maximum: ceftazidime 2 g + avibactam 0.5 g
  • Infusion time: 2 hours 1

Ages 6 Months to <2 Years

  • Dose: 62.5 mg/kg IV every 8 hours
    • Ceftazidime 50 mg/kg + avibactam 12.5 mg/kg
  • Infusion time: 2 hours 1

Ages 3 to <6 Months

  • Dose: 50 mg/kg IV every 8 hours
    • Ceftazidime 40 mg/kg + avibactam 10 mg/kg
  • Infusion time: 2 hours 1

Ages >28 Days to <3 Months (or corrected age >28 days for preterm)

  • Dose: 37.5 mg/kg IV every 8 hours
    • Ceftazidime 30 mg/kg + avibactam 7.5 mg/kg
  • Infusion time: 2 hours 1

Neonates ≤28 Days (Gestational Age ≥31 Weeks)

  • Dose: 25 mg/kg IV every 8 hours
    • Ceftazidime 20 mg/kg + avibactam 5 mg/kg
  • Infusion time: 2 hours 1

Pediatric Renal Impairment (Ages ≥2 Years)

eGFR (mL/min/1.73 m²) Dose Frequency
31-50 31.25 mg/kg (max 1.25 g) Every 8 hours
16-30 23.75 mg/kg (max 0.94 g) Every 12 hours
6-15* 23.75 mg/kg (max 0.94 g) Every 24 hours
≤5* 23.75 mg/kg (max 0.94 g) Every 48 hours

*Administer after hemodialysis on dialysis days 1

Note: There is insufficient data to recommend dosing for children <2 years with renal impairment 1, 3.

Special Populations

Hepatic Impairment

No dose adjustment required—neither ceftazidime nor avibactam undergo significant hepatic metabolism 1

Elderly Patients

No dose adjustment based on age alone, but adjust for renal function as elderly patients commonly have reduced creatinine clearance 1

Critically Ill Patients

Consider extended infusion (3 hours instead of 2 hours) or therapeutic drug monitoring, particularly in patients with augmented renal clearance or severe infections 4, 5. Recent data suggests that standard dosing may be suboptimal in critically ill patients with rapidly changing renal function 6.

Key Clinical Considerations

  • Renal monitoring is mandatory: Both drugs are almost exclusively renally eliminated, making daily monitoring of renal function essential in hospitalized patients 1
  • Hemodialysis timing: Both drugs are extensively removed by hemodialysis (approximately 55% in 4 hours), so always dose after dialysis 1
  • Combination therapy for cIAI: Always add metronidazole for anaerobic coverage in intra-abdominal infections 7
  • Pregnancy: No specific contraindications, but avoid doxycycline alternatives; use standard dosing 1

Related Questions

What is the appropriate ceftazidime‑avibactam dosing for a patient with a creatinine clearance of about 3 mL/min (severe renal impairment)?
How should the dosing of ceftazidime‑avibactam be adjusted for renal impairment?
What is the recommended dosing regimen of ceftazidime‑avibactam, including renal dose adjustments, for treating complicated intra‑abdominal infections, complicated urinary tract infections, and hospital‑acquired or ventilator‑associated pneumonia?
What is the appropriate oral cefpodoxime dose for a pediatric patient (≥6 months) per kilogram for routine versus severe infections, and how should the dose be adjusted for renal impairment?
What is the appropriate dosing regimen of Zerbaxa (ceftazidime‑avibactam) for a 76‑year‑old male, weighing 95 kg, height 180 cm, with impaired renal function (serum creatinine 134 µmol/L) after spine fracture surgery, who is currently receiving piperacillin‑tazobactam (Tazocin) empirically?
What is the recommended starting dose and titration schedule for cilnidipine in adults, including adjustments for elderly patients or those with moderate renal or hepatic impairment?
In a 7-year-old child with Raynaud phenomenon and systemic vasculitis, what cardiac complications should be evaluated and how should they be managed?
What prednisone taper regimen should be used to treat a rash from systemic therapy side effects in a patient with cutaneous T‑cell lymphoma?
What is the recommended initial dose of hydroxychloroquine for systemic lupus erythematosus?
What constitutes a significant increase in serum creatinine after initiating heart‑failure therapy?
How can an adult patient with obesity (BMI ≥ 30 kg/m² or ≥ 27 kg/m² with a comorbidity) safely access and use retatrutide?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.